1. Histone Deacetylase Inhibitors Enhance Lexatumumab-Induced Apoptosis via a p21Cip1-Dependent Decrease in Survivin Levels
   Steffan T. Nawrocki et al, 2007, Cancer Research CrossRef
2. Diallyl trisulfide increases the effectiveness of TRAIL and inhibits prostate cancer growth in an orthotopic model: molecular mechanisms
   Sharmila Shankar et al, 2008, Molecular Cancer Therapeutics CrossRef
3. Dissecting Histone Deacetylase 3 in Multiple Disease Conditions: Selective Inhibition as a Promising Therapeutic Strategy
   Nilanjan Adhikari et al, 2021, Journal of Medicinal Chemistry CrossRef
4. Natural Killer Cell Response to Chemotherapy-Stressed Cancer Cells: Role in Tumor Immunosurveillance
   Alessandra Zingoni et al, 2017, Frontiers in Immunology CrossRef
5. Epigenetic Metalloenzymes
   Christophe Blanquart et al, 2019, Current Medicinal Chemistry CrossRef
6. Understanding Apoptosis and Apoptotic Pathways Targeted Cancer Therapeutics
   Rehmat Jan et al, 2019, Advanced Pharmaceutical Bulletin CrossRef
7. Sulforaphane Enhances the Therapeutic Potential of TRAIL in Prostate Cancer Orthotopic Model through Regulation of Apoptosis, Metastasis, and Angiogenesis
   Sharmila Shankar et al, 2008, Clinical Cancer Research CrossRef
8. Experimental therapy of malignant gliomas using the inhibitor of histone deacetylase MS-275
   Ilker Y. Eyüpoglu et al, 2006, Molecular Cancer Therapeutics CrossRef
9. Interactive Effects of HDAC Inhibitors and TRAIL on Apoptosis Are Associated with Changes in Mitochondrial Functions and Expressions of Cell Cycle Regulatory Genes in Multiple Myeloma
   Tamer E. Fandy et al, 2005, Neoplasia CrossRef